Resverlogix Corp.

RVX

CA76128M1086

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:06:29 2024-04-26 pm EDT			5-day change	1st Jan Change
0.06 ^CAD	+9.09%		+9.09%	-14.29%

Apr. 01	Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 21	Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors	CI

Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2021

April 31, 2022 at 06:36 pm EDT

Resverlogix Corp. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 24.77 million.

Basic loss per share from continuing operations was USD 0.1. Diluted loss per share from continuing operations was USD 0.1.

Latest news about Resverlogix Corp.

Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors	Feb. 20	CI
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Resverlogix Corp. Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes	23-10-04	CI
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Transcript : Resverlogix Corp. - Shareholder/Analyst Call	23-06-19
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Resverlogix Corp. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions	22-09-28	MT
Resverlogix up 4% as Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22-08-22	MT
Resverlogix Publishes New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22-08-22	MT
Resverlogix Brief: Publishing New Data Highlighting Apabetalone's Benefit in Non-alcoholic Fatty Liver Disease	22-08-22	MT
Resverlogix Corp. Announces Management Changes	22-08-15	CI
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Resverlogix Corp. Appoints Dicky To as Director	22-06-21	CI
Transcript : Resverlogix Corp. - Shareholder/Analyst Call	22-06-21
Resverlogix Reports Research Highlighting Safety of BD2-selective BET Inhibitors; Shares Fell 12% on Tuesday	22-06-08	MT
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Resverlogix Announces Type C Meeting with FDA For Phase 3 High-Risk COVID-19 Outpatient Study	22-05-09	MT
U.S. Food and Drug Administration Grants Resverlogix Corp. Request for Type C Meeting to Review Clinical Trial Protocol for Phase 3 Study	22-05-09	CI
Resverlogix Brief: Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study	22-05-09	MT
Resverlogix Details One-Year Extension of Debenture	22-04-19	MT
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RESVERLOGIX CORP.	-14.29%	12.03M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B